Free Trial

HCW Biologics Q2 2023 Earnings Report

HCW Biologics logo
$0.45 +0.04 (+8.72%)
(As of 12/20/2024 05:40 PM ET)

HCW Biologics EPS Results

Actual EPS
-$0.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

HCW Biologics Revenue Results

Actual Revenue
$0.62 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HCW Biologics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

HCW Biologics Earnings Headlines

Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
HCW Biologics Expands with New Financial Agreements
HCW Biologics licenses proprietary preclinical molecule to WY Biotech
See More HCW Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email.

About HCW Biologics

HCW Biologics (NASDAQ:HCWB), a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

View HCW Biologics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings